French PE firm Jeito Capital held a $1.2 billion final close for its second biopharma fund, as investors bet that Big Pharma’s $180 billion patent cliff will create more attractive opportunities in the space.
Jeito II beat its target and is almost double the size of its predecessor, which closed on $630 million in 2021. Fund II also has a higher average ticket size of €150 million (about $175.7 million) and is aiming to back 15 to 20 companies.
The fund invests in clinical-stage biopharma companies that develop therapies for severe diseases with high unmet medical needs. It invests primarily in Europe and has already deployed in therapeutic areas including obesity, reproductive medicine, oncology, autoimmune and inflammatory diseases, neurology and cardio-metabolic diseases.
With the new fund, Jeito Capital now manages €1.6 billion in assets.
The biopharma industry is bracing for a period of strong M&A ahead of the next patent cliff by 2030, which puts $180 billion of pharma companies’ revenue at risk.
A patent cliff occurs when the blockbuster drugs of a pharmaceutical company lose patent exclusivity, allowing generic or biosimilar products to enter the market.
Pharmaceutical companies typically turn to acquisitions of smaller companies with newly approved or nearly approved drugs to fill the gap. The stronger M&A market could provide investors with more exit opportunities amid inflated valuations over the past few years.
M&A deal value in Europe’s biotechnology sector so far this year has already surpassed last year’s total, with over €1.8 billion transacted, according to PitchBook data. Most of it came from Honeywell‘s agreement to acquire UK-based Johnson Matthey‘s catalyst technologies business segment for £1.3 billion (about $1.8 billion) in February.
Recent News
Q&A: Bullhound’s Alon Kuperman on Revolut’s path to $1T
Former Carlyle Asia and Warburg Pincus execs launch pan-Asian secondaries fund
Learn about our editorial standards.